IP Library Granted Patent US 7,186,423
Granted Patent B2
US 7,186,423 · App. 10/690,628 · Granted Mar 6, 2007

Processes of making North American ginseng fractions, products containing them, and uses as immunomodulators

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,186,423
App. No.
10/690,628
Granted
Mar 6, 2007
Kind
B2
Abstract

The invention is directed to chemical processes of preparing fractions from North American ginseng ( Panax quinquefolium ) and pharmaceutical compositions containing these fractions. The products of the present invention may be used to stimulate the production of cytokines and/or antibodies, or as therapeutics targeted at conditions characterized by low immunity, such as the common cold, influenza, chronic fatigue syndrome, AIDS and cancer.

Claims (9)

1. A pharmaceutical compositions, wherein said pharmaceutical composition comprises ginseng fraction CVT-E002 and a pharmaceutically acceptable carrier.

2. A method of preparing a pharmaceutical composition suitable for treating a condition characterized by low immunity, wherein said method comprises combining an effective amount of ginseng fraction CVT-E002 and, optionally, an effective amount of another medicament that is suitable for treating a condition characterized by low immunity with at least one pharmaceutically acceptable excipient to produce a pharmaceutical composition suitable for treating a condition characterized by low immunity.

3. The method of claim 2 , wherein the condition is selected from the group consisting of common cold, influenza, chronic fatigue syndrome, AIDS and cancer.

4. A method of stimulating the production of IL-1, IL-6 and/or TNF-α in cells, wherein said method comprises contacting said cells with an effective amount of ginseng fraction CVT-E002.

5. A method of activating B-lymphocyte proliferation and antibody production resulting from said B-lymphocyte proliferation in a patient in need of such proliferation, wherein said method comprises administering to the patient an effective amount of ginseng fraction CVT-E002.

6. A method of treating a condition characterized by low immunity in a patient in need thereof, comprising administering to the patient an effective amount of ginseng fraction CVT-E002.

7. The method of claim 6 , wherein the condition is selected from the group consisting of common cold, influenza, chronic fatigue syndrome, AIDS and cancer.

8. A method of stimulating the in vitro production of immunoglobulins in cells, wherein said method comprises contacting cells with an effective amount of ginseng fraction CVT-E002.

9. A method of stimulating the in vivo production of immunoglobulins in a subject in need thereof, wherein said method comprises administering to the subject an effective amount of ginseng fraction CVT-E002.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Dec 23, 2010
From: FX LIFE SCIENCES AG
To: THE BANK OF NOVA SCOTIA
Reel/Frame 025570/0983 →
ASSIGNMENT OF SECURITY INTEREST Recorded Oct 21, 2009
From: FX LIFE SCIENCES AG
To: BANK OF NOVA SCOTIA, THE
Reel/Frame 023401/0909 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2008
From: FX LIFE SCIENCES INTERNATIONAL GMBH
To: FX LIFE SCIENCES AG
Reel/Frame 022012/0925 →
SECURITY AGREEMENT Recorded Oct 11, 2007
From: FX LIFE SCIENCES INTERNATIONAL GMBH
To: THE BANK OF NOVA SCOTIA
Reel/Frame 019943/0373 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2006
From: CV TECHNOLOGIES, INC.
To: FX LIFE SCIENCES INTERNATIONAL GMBH
Reel/Frame 018420/0325 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2006
From: CV TECHNOLOGIES, INC.
To: FX LIVE SCIENCES INTERNATIONAL GMBH
Reel/Frame 018323/0483 →